Anti-Cancer Agent, Herceptin® Obtained Approval for Additional Indication of Advanced or Recurrent Gastric Cancer Overexpressing HER2, Not Amenable to Curative Resection
Mar 10, 2011
Anti-Cancer Agent, Herceptin® Obtained Approval for Additional Indication of Advanced or Recurrent Gastric Cancer Overexpressing HER2, Not Amenable to Curative Resection
Anti-Cancer Agent, Herceptin® Obtained Approval for Additional Indication of Advanced or Recurrent Gastric Cancer Overexpressing HER2, Not Amenable to Curative Resection
